Sector
PharmaceuticalsOpen
₹899Prev. Close
₹902.15Turnover(Lac.)
₹845.39Day's High
₹906.2Day's Low
₹876.952 Week's High
₹1,303.952 Week's Low
₹725.2Book Value
₹275.33Face Value
₹2Mkt Cap (₹ Cr.)
17,705.42P/E
35.97EPS
25.05Divi. Yield
1.2221 Jun 2024
12:00 AM
AGM
Announcement Date: 21 Jun, 2024
18 Apr 2025
12:00 AM
Board Meeting
Agenda : Audited Result
9 May 2024
12:00 AM
Dividend
Dividend Amount: 11
Record Date: 15 Jul, 2024
EBITDA was up 9% at ₹286 crore, with EBITDA margin at 16% of total sales, reflecting operating efficiency.
The approved product is the generic equivalent of Tegretol Tablets 200 mg, which was initially developed by Novartis Pharmaceuticals Corporation.
This approval bolsters Alembic's portfolio in the United States market and reinforces its presence in injectable segment
Following an inspection carried out from Nov 14-22 2024, the facility was cited as being ‘VAI’ (Voluntary Action Indicated).
EBITDA margin came in at 15.4% in the quarter under review as compared to 16.30% in the previous corresponding period.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 39.31 | 39.31 | 39.31 | 39.31 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 4,869.6 | 4,374.99 | 5,251.03 | 5,062.5 |
Net Worth | 4,908.91 | 4,414.3 | 5,290.34 | 5,101.81 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 5,051.44 | 4,132.55 | 2,945.26 | 2,985.9 |
yoy growth (%) | 22.23 | 40.31 | -1.36 | -0.76 |
Raw materials | -1,297.91 | -1,045.89 | -892.73 | -886.29 |
As % of sales | 25.69 | 25.3 | 30.31 | 29.68 |
Employee costs | -948.27 | -806.37 | -582.72 | -527.46 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 1,416.6 | 1,176.79 | 535.23 | 549.71 |
Depreciation | -152.6 | -135.67 | -101.76 | -82.9 |
Tax paid | -241.21 | -197.39 | -113.25 | -119.08 |
Working capital | -16.69 | 598.87 | 208.77 | -67.37 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 22.23 | 40.31 | -1.36 | -0.76 |
Op profit growth | 30.7 | 90.16 | -0.1 | -35.56 |
EBIT growth | 18.91 | 123.64 | -2.79 | -39.74 |
Net profit growth | 21.24 | 129.72 | -2 | -38.36 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 6,672.08 | 6,228.63 | 5,652.62 | 5,305.79 | 5,393.13 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 6,672.08 | 6,228.63 | 5,652.62 | 5,305.79 | 5,393.13 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 56.3 | 28.31 | 2.74 | 55.74 | 87.29 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,744.8 | 132.89 | 4,18,647.96 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,025.5 | 76.85 | 1,59,310.35 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,480 | 25.66 | 1,19,409.63 | 1,438.15 | 0.88 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,141.2 | 58.21 | 1,06,184.18 | 485 | 0.89 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,408.2 | 51.49 | 99,569.64 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & CEO
Chirayu R Amin
Director (Finance) & CFO
Rajkumar Baheti
Managing Director
Pranav Amin
Managing Director
Shaunak Amin
Independent Director
Archana Hingorani
Independent Director
Ashok Barat
Company Sec. & Compli. Officer
Manisha Saraf
Independent Director
Jai S Diwanji
Independent Director
Manish Kejriwal
Independent Director
Geeta Goradia
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Alembic Pharmaceuticals Ltd
Summary
Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world. The companys state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited. The company is engaged in pharmaceuticals business. As per the Scheme of Arrangement, the Pharmaceutical Undertaking of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement. The shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus, the company became an associate of Alembic Ltd.In September 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange. During 2012, Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. During 2013, the company got USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement wit
Read More
What is the Alembic Pharmaceuticals Ltd share price today?
The Alembic Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹900.75 today.
What is the Market Cap of Alembic Pharmaceuticals Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alembic Pharmaceuticals Ltd is ₹17705.42 Cr. as of 09 May ‘25
What is the PE and PB ratio of Alembic Pharmaceuticals Ltd?
The PE and PB ratios of Alembic Pharmaceuticals Ltd is 35.97 and 3.41 as of 09 May ‘25
What is the 52 Week High and Low of Alembic Pharmaceuticals Ltd?
The 52-week high/low is the highest and lowest price at which a Alembic Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Alembic Pharmaceuticals Ltd is ₹725.2 and ₹1303.9 as of 09 May ‘25
What is the CAGR of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd's CAGR for 5 Years at 3.29%, 3 Years at 7.53%, 1 Year at -10.13%, 6 Month at -13.10%, 3 Month at 1.59% and 1 Month at 6.27%.
What is the shareholding pattern of Alembic Pharmaceuticals Ltd?
The shareholding pattern of Alembic Pharmaceuticals Ltd is as follows:
Promoters - 69.67 %
Institutions - 20.37 %
Public - 9.96 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
